MTOR and nonpapillary renal cell carcinoma: Similar results were achieved for AKT3 and mTOR; AKT3 was found to be positively correlated with a favorable prognosis in stage III and IV patients with ccRCC [HR 95% CI = 0.45 (0.25–0.81); 0.50 (0.27–0.94), respectively] and the overexpression of mTOR was correlated with an improved OS in stage I and II patients with ccRCC [HR 95% CI = 0.30 (0.12–0.77); 0.24 (0.06–0.86), respectively].